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Introduction {#sec001}
============

The menstrual cycle involves a complex interaction between the ovaries and the hypothalamus and pituitary in the brain. During the cycle, gonadotropin releasing hormone (GnRH) produced by the hypothalamus and ovarian hormones affect the anterior pituitary. In response the pituitary releases gonadotropins including luteinizing hormone (LH) and follicular stimulating hormone (FSH). These gonadotropins stimulate the ovarian system controlling follicle growth and hormone production. The hormones produced by the follicles, notably estradiol (E2), progesterone (P4), and inhibin A (InhA), feedback onto the brain influencing pituitary hormone production \[[@pcbi.1007848.ref001]\].

Hormonal contraception has been in development since the early 20th century with the first FDA approved contraception appearing in 1960 \[[@pcbi.1007848.ref002], [@pcbi.1007848.ref003]\]. Hormonal contraceptives were mainly composed of synthetic progesterone (a progestin) or a progestin and a synthetic estrogen such as ethinyl estradiol. If these hormones are introduced individually, each can cause contraceptive effects, but high doses of hormonal contraceptives increase the risk for cardiovascular events most notable venous thromboembolism (VTE) and myocardial infarction (MI) \[[@pcbi.1007848.ref003]--[@pcbi.1007848.ref010]\]. Combined hormonal contraceptives (ethinyl estradiol and progestin together) were discovered during testing of a progestin based contraceptive that was accidentally contaminated with a form of estrogen and shown to increase cycle stability and decrease unwanted bleeding patterns \[[@pcbi.1007848.ref011]\]. One way to study the effect of administering a combined dose is to use mathematical modeling, which can provide additional insight into effects of varying progestin and synthetic estrogen type and dose.

A number of mathematical models capture dynamics of normal cycling, many of which are based on the formulation by Schlosser and Selgrade \[[@pcbi.1007848.ref012], [@pcbi.1007848.ref013]\]. These models are on a time scale of days and predict mean levels of hormone \[[@pcbi.1007848.ref014], [@pcbi.1007848.ref015]\]. To our knowledge there have been no adaptations of mathematical models to predict contraceptive effects of exogenous progesterone and estrogen. Specifically, the original menstrual cycle models by Clark et al. \[[@pcbi.1007848.ref014]\] and Margolskee and Selgrade \[[@pcbi.1007848.ref015]\] do not include ovarian autocrine effects, and therefore they cannot predict the contraceptive response to exogenous administration of progestins.

The model developed in this study, including ovarian autocrine effects, is used to test hormonal contraceptive treatments via oral administration of ethinyl estradiol and progestin. These treatments are modeled by modifying state variables for blood concentrations of E2 and P4. The model does not include a pharmacodynamic component determining how much or how long it takes for specific amounts of oral contraceptives to produce specific changes in the amount of E2 and P4. Therefore, we administer ethinyl estradiol and progestin as concentrations and assume that contraception is attained if model simulations show a reduction in the LH surge to non-ovulatory levels and/or in P4 levels throughout the cycle.

Model simulations confirm that low and high doses of exogenous progestin reduce the LH surge to non-ovulatory levels as suggested by clinical data \[[@pcbi.1007848.ref016], [@pcbi.1007848.ref017]\] for progestin treatments. Also low and high doses of exogenous estrogen reduce the LH surge to non-ovulatory levels. And a combination of low dose estrogen and low dose progestin administered together result in constant non-ovulatory hormone levels. The model may be used to predict which dosing levels of estrogen and progestin produce contraceptive cycles. In addition, model simulations indicate how quickly a combined contraceptive treatment produces a non-ovulatory menstrual cycle and how fast the cycle returns to normal after the treatment ends. These simulations were done to motivate clinical experimentation with similar contraceptive combinations.

Methods {#sec002}
=======

In this section we discuss the hormonal characteristics of the menstrual cycle, important mechanisms contributing to a contraceptive state, and mechanistic modeling of both the normal menstrual cycle and contraception. Parameter values and dimensions used in the model are found in [Table 1](#pcbi.1007848.t001){ref-type="table"}.

10.1371/journal.pcbi.1007848.t001

###### Parameter values.

![](pcbi.1007848.t001){#pcbi.1007848.t001g}

  Hypothalamus/Pituitary   Ovaries                                                                                                                          
  ------------------------ --------- ------------- ------------------- ------- ------------------------------------------ ---------------- ---------------- -------------
  *V*~0,*LH*~              500       IU/day        **b**               0.34    $\frac{L}{IU}\frac{\mu g}{day}$            *e*~0~           30               pg/mL
  *V*~1,*LH*~              4500      IU/day        \**Ki*~*RcF*,*P*~   1       mL/ng                                      **e**~**1**~     0.30             L^−1^
  **Km**~**LH**~           175       mL/pg         \****ξ***           2.2     (none)                                     **e**~**2**~     0.80             L^−1^
  *Ki*~*LH*,*P*~           12.2      mL/ng         **c**~**1**~        0.25    $\frac{L}{IU}\frac{1}{day}$                **e**~**3**~     1.67             L^−1^
  *k*~*LH*~                2.42      day^−1^       *c*~2~              0.07    ${(\frac{L}{IU})}^{\alpha}\frac{1}{day}$   **p**~**0**~     0.8              ng/mL
  *c*~*LH*,*P*~            0.26      mL/ng         *c*~3~              0.027   $\frac{L}{IU}\frac{1}{day}$                **p**~**1**~     0.15             kL^−1^
  *c*~*LH*,*E*~            0.004     mL/pg         *c*~4~              0.51    ${(\frac{L}{IU})}^{\gamma}\frac{1}{day}$   **p**~**2**~     0.13             kL^−1^
  *a*~*LH*~                14        day^−1^       *d*~1~              0.5     day^−1^                                    \**Km*~*Papp*~   75               mL/ng
  *v*~*FSH*~               375       IU/day        *d*~2~              0.56    day^−1^                                    \**μ*            8                (none)
  *τ*                      1.5       day           **k**~**1**~        0.69    day^−1^                                    *h*~0~           0.4              IU/mL
  **Ki**~**FSH,InhA**~     1.75      IU/mL         **k**~**2**~        0.86    day^−1^                                    *h*~1~           0.009            IU/(*μ*gmL)
  *k*~*FSH*~               1.9       day^−1^       *k*~3~              0.85    day^−1^                                    *h*~2~           0.029            IU/(*μ*gmL)
  *c*~*FSH*,*P*~           12        mL/ng         *k*~4~              0.85    day^−1^                                    *h*~3~           0.018            IU/(*μ*gmL)
  *c*~*FSH*,*E*~           0.0018    mL^2^/pg^2^   *α*                 0.79    (none)                                     *p*~*dose*~      0, 0.6, or 1.3   ng/mL
  *a*~*FSH*,*E*~           8.21      day^−1^       *γ*                 0.02    (none)                                     *e*~*dose*~      0, 40, or 92     pg/mL
  *v*                      2.5       L                                                                                                                      

Parameters new to this model are marked with a \*

The normal menstrual cycle {#sec003}
--------------------------

This section outlines phases and contributing hormones associated with a normal menstrual cycle \[[@pcbi.1007848.ref001]\]. [Fig 1](#pcbi.1007848.g001){ref-type="fig"} depicts the phases of the menstrual cycle and the production and the action of associated hormones. The menstrual cycle arises from a complex interaction between the hypothalamus and the pituitary in the brain, and the ovaries. In the brain a system of capillaries forms a small portal system of blood flow from the hypothalamus to the anterior pituitary, which gives the hypothalamus the means for communicating with the pituitary in absence of a direct neural connection. The hypothalamus secretes GnRH into the portal system stimulated by ovarian hormones and feedback from pituitary gonadotropins, and because the half-life of GnRH is short (2-4 minutes), it is only in the portal system that effective levels are found. To facilitate this, GnRH is released in a pulsatile fashion that changes in both magnitude and frequency in response to feedback from ovarian hormones and pituitary gonadotropins. These pulsatile secretions are relatively fast taking place every 1-3 hours depending on menstrual cycle phase, and a wide variability exists amongst individuals \[[@pcbi.1007848.ref001]\]. The pulsatile stimulation from GnRH influences the anterior pituitary synthesis and release of gonadotropins (including LH and FSH) influencing the ovaries.

![Menstrual cycle phases.\
The outer ring represents ovarian development starting with menstruation (black oval, top) and proceeding in a clockwise direction through the follicular phase (blue ovals, right), ovulation (black oval, bottom), and the luteal phase (red ovals, left). The ovary produces estrodial (E2), progesterone (P4), and inhibin A (InhA), while the brain produces FSH and LH. Directed solid arrows indicate the action of hormones at various stages of the cycle.](pcbi.1007848.g001){#pcbi.1007848.g001}

The menstrual cycle consists of two phases (see [Fig 1](#pcbi.1007848.g001){ref-type="fig"}): the follicular phase and the luteal phase. In the weeks before a woman is born her ovaries produce a large mass of germ cells (6-7 million); no more will be produced during her lifetime. Germ cells are transformed by mitosis and a meiotic division into an oocyte. Pre-granulosa cells envelop an oocyte and the resulting unit is called a primordial follicle. This process will eventually happen to all oocytes. As the follicle grows and the surrounding granulosa cell layer proliferates, it becomes a primary follicle. From primary follicle stage it is believed that about 85 days pass before ovulation; most of this time is spent without the influence of pituitary gonadotropins.

The follicular phase begins when multiple follicles are "recruited" and begin expressing FSH receptors, which when stimulated support follicle growth. Further growth leads to LH receptor expression facilitating follicle production of ovarian hormones (including P4, E2, and InhA). The follicles compete for FSH (and later LH) and one or more follicles will advance to ovulation, if sufficiently stimulated by gonadotropins. Follicles may be arrested at any point during this process through a process of atresia consisting of a break down in granulosa activity eventually ending in apoptosis. All follicles that are "recruited" and unable to reach ovulation will go through this process. During ovulation the follicle ruptures and releases the oocyte through complex mechanisms, for details see \[[@pcbi.1007848.ref001]\]. The granulosa cells on the ruptured follicle are luteinized and the structure becomes the corpus luteum. This marks the beginning of the luteal phase during which the oocyte (now called an ovum) is ready for fertilization and the corpus luteum produces P4 and E2 with support from low levels of LH. After about 14 days if fertilization has not taken place, menstruation occurs and the cycle begins again.

E2 has a two stage effect on pituitary LH: at low levels LH release is inhibited but at a certain concentration E2 triggers a massive production of LH. In the beginning of the follicular phase, follicles produce small amounts of E2 inhibiting LH release. As a follicle develops into a dominant follicle, it begins producing E2 in much larger quantities until the second stage effect of E2 causes large amounts of LH to be produced. This mid-cycle rise in LH is called the LH surge and marks the end of the follicular phase. This massive change in synthesis stimulated by E2 is necessary for ovulation. Near the end of the follicular phase InhA is secreted by the follicles, which reduces production of FSH and aids entering the luteal phase. After ovulation the corpus luteum begins producing large amounts of P4 and InhA. In the late luteal phase production of P4 and InhA decreases allowing for increase FSH and E2 production; both priming the cycle for the next follicular phase.

Contraceptive mechanisms {#sec004}
------------------------

There is not a specific clinical marker of contraception although many indicators can be used: lack of LH surge, a lack of rise in luteal phase progesterone, or incomplete follicle development. Since it is not feasible to determine cycle timing if ovulation does not occur, contraceptive studies measure progesterone daily, and if P4\< 5 ng/mL it is assumed that ovulation is suppressed \[[@pcbi.1007848.ref016]\], i.e., P4 can be used as a surrogate marker for contraceptive efficacy. Low progesterone levels or the absence of an LH surge indicates that ovulation and luteinization have not occurred or have not occurred properly. In addition to hormonal effects \[[@pcbi.1007848.ref016], [@pcbi.1007848.ref018]\], there are physical indicators such as increased cervical mucus viscosity, which can prevent sperm mobility leading to a contraceptive state.

Physiologically, progestin can cause a contraceptive state through multiple mechanisms. The primary is prevention of ovulation, but secondary effects such as thickening of cervical mucus also cause a contraceptive state \[[@pcbi.1007848.ref016], [@pcbi.1007848.ref019], [@pcbi.1007848.ref020]\]. According to \[[@pcbi.1007848.ref016]\] ovulation prevention occurs if there is not enough estradiol production to stimulate positive feedback mechanisms necessary for the LH surge. The lack of estradiol production is due to poor follicle development from inadequate LH and FSH support. Progestin reduces LH synthesis directly \[[@pcbi.1007848.ref001]\] and by limiting follicular sensitivity to FSH in the early follicular phase \[[@pcbi.1007848.ref016], [@pcbi.1007848.ref021]\]. The original models by Clark et al. \[[@pcbi.1007848.ref014]\] and Margolskee and Selgrade \[[@pcbi.1007848.ref015]\] include progesterone's effect on LH synthesis but do not include progesterone's limiting effect on follicle development via sensitivity to FSH. As a result the original models fail to reproduce contraceptive behavior when administration of exogenous progestins. To capture this effect, our new model introduces a growth limiting factor affecting the early follicle development. Similar to progestins, estrogens act through multiple mechanisms. The primary mechanisms are suppression of LH release by the pituitary \[[@pcbi.1007848.ref022]\], included in the models \[[@pcbi.1007848.ref014], [@pcbi.1007848.ref015]\], and bolstering progesterone's contraceptive effect \[[@pcbi.1007848.ref001], [@pcbi.1007848.ref023]\], which is not accounted for in the original models. In the model presented here, the latter is included by multiplying progesterone, P4, by an increasing function of estrogen, E2.

The major mechanism of progestin in a combined hormonal contraceptive treatment is the same, limiting the sensitivity of follicles to gonadotropins. Estrogen serves two purposes: to limit gonadotropin secretion from the pituitary \[[@pcbi.1007848.ref001], [@pcbi.1007848.ref024]\], which is effective enough to cause a contraceptive state from estrogen only dosing, and to increase progesterone receptor expression, which increases progesterone's effectiveness \[[@pcbi.1007848.ref001]\].

In summary, contraception can be achieved either by administering exogenous progestins, estrogen, or a combination of the two. This study uses modeling to illustrate that the combined treatment is advantageous because contraception can be achieved by administrating significantly lower doses of each hormone.

Data {#sec005}
----

Data used in this study were extracted from previously published studies \[[@pcbi.1007848.ref016], [@pcbi.1007848.ref018], [@pcbi.1007848.ref025]\]. Time-series data were digitized and mean values extracted from published Figures and Tables.

Time-series data and error bars for the normal menstrual cycle are digitized from Figure 1 in Welt et al. \[[@pcbi.1007848.ref025]\]. These data report mean daily hormone values and variation for FSH, LH, E2, P4, and InhA for 28 days averaged over a group of 23 normally cycling women. These data, repeated over three cycles are shown in [Fig 3](#pcbi.1007848.g003){ref-type="fig"} together with baseline modeling results.

Data for progestin based contraception are taken from Figure 1 and Table 3 in Obruca al. \[[@pcbi.1007848.ref016]\]. These data include hormone values for FSH, LH, E2, and P4 for three doses of Org 30659 progestin administered daily for 21 days. From this study, we extract: mean maximum P4, mean E2, mean maximum FSH, mean maximum LH, and corresponding standard deviations over the 21 day treatment period.

The combined hormonal contraception simulations are compared with data from Figure 1 and Table 3 in Mulders and Dieben \[[@pcbi.1007848.ref018]\], which tests effectiveness on ovarian function of a vaginal ring, NuvaRing, containing both a progestin and an estrogen. From this study we compare simulations to data for median maximum hormonal levels for FSH, LH, E2, and P4 for subjects receiving combined hormonal treatment administered vaginally.

Modeling the normal menstrual cycle {#sec006}
-----------------------------------

Two components are used to form the menstrual cycle model. The first is a lumped model of the hypothalamus and the pituitary, which predicts synthesis and release of gonadotropins based on circulating concentrations of ovarian hormones (E2, InhA, P4). The second includes the ovaries, accounting for ovarian stages in conjunction with auxiliary equations predicting ovarian hormone production. [Fig 2](#pcbi.1007848.g002){ref-type="fig"} illustrates the two model components dividing the menstrual cycle into multiple stages representing amount of active tissue in each stage. This distribution of active tissue is used to predict production of ovarian hormones.

![Full model diagram.\
The model diagram shows all states broken into two sub-models. The hypothalamus/pituitary model has four states (RP~FSH~,FSH,RP~LH~, LH) and the ovarian model has nine states (RcF, GrF, DomF, Sc1, Sc2, Lut1-4). In the hypothalamus/pituitary model, the black horizontal arrows represent hormone (E2, Papp) movement and in the ovarian model they represent movement of cells or tissue (mediated by LH) between stages. The red horizontal arrows represent output from a sub-model, and the green horizontal arrows represent input into a sub-model. A hormone *H* written as *H*^+^ or *H*^−^ has a stimulating or inhibiting effect respectively on movement between chambers or effectiveness of a hormone within the chamber. The blue dashed-dotted lines within the ovarian model show stages contributing to ovarian hormone production in the auxiliary equations. The gray dashed lines in the ovarian model represent autocrine influence of ovarian hormones within the model. Full expression for the hypothalamus/pituitary and ovarian models can be found in Eqs ([1](#pcbi.1007848.e006){ref-type="disp-formula"})--([4](#pcbi.1007848.e009){ref-type="disp-formula"}) and Eqs ([5](#pcbi.1007848.e010){ref-type="disp-formula"})--([13](#pcbi.1007848.e018){ref-type="disp-formula"}), respectively, and parameter values and dimensions are listed in [Table 1](#pcbi.1007848.t001){ref-type="table"}.](pcbi.1007848.g002){#pcbi.1007848.g002}

### Hypothalamus and pituitary model {#sec007}

The lumped model (Eqs ([1](#pcbi.1007848.e006){ref-type="disp-formula"})--([4](#pcbi.1007848.e009){ref-type="disp-formula"})) of the hypothalamus and pituitary predicts synthesis and release of FSH and LH as a function of serum concentrations of E2, P4, and InhA. Parameter values and dimensions for Eqs ([1](#pcbi.1007848.e006){ref-type="disp-formula"})--([4](#pcbi.1007848.e009){ref-type="disp-formula"}) can be found in [Table 1](#pcbi.1007848.t001){ref-type="table"}. Dynamics of each pituitary hormone consists of two equations (Eqs ([1](#pcbi.1007848.e006){ref-type="disp-formula"}) and ([2](#pcbi.1007848.e007){ref-type="disp-formula"}) for LH and Eqs ([3](#pcbi.1007848.e008){ref-type="disp-formula"}) and ([4](#pcbi.1007848.e009){ref-type="disp-formula"}) for FSH).

The reserve pool of LH (*RP*~*LH*~), [Eq (1)](#pcbi.1007848.e006){ref-type="disp-formula"}, tracks the mass of stored gonadotropin LH within the pituitary and is composed of two terms: a positive term representing synthesis and a negative term representing release. The synthesis is promoted by estrogen modeled using a Hill function in *E*~2~, and inhibited by progesterone contained in the *P*~*app*~ term in the denominator. *P*~*app*~, defined in [Eq (16)](#pcbi.1007848.e021){ref-type="disp-formula"}, is as a product of *P*~4~ and scaled progesterone receptor expression. Hence, *P*~*app*~ measures the progesterone signal in the system. The release is promoted by *P*~*app*~ and inhibited by *E*~2~. The blood hormone concentration *LH* consists of a positive term, denoting the release from the reserve pool scaled by blood volume (*v*), and a negative linear term representing clearance of the hormone from the blood.

Similarly, the reserve pool of FSH (*RP*~*FSH*~), [Eq 3](#pcbi.1007848.e008){ref-type="disp-formula"}, tracks the mass of stored gonadotropin FSH within the pituitary. It is also composed of two terms: a synthesis term inhibited by inhibin A (*InhA*) and a release term that similar to *RP*~*LH*~ is promoted by *P*~*app*~ and inhibited by *E*~2~. It should be noted that the biological process for inhibin A's effect is lengthy (it takes approximately 1.5 days for this to have an effect \[[@pcbi.1007848.ref026]\]). To include this effect, we introduce a discrete time-delay *InhA*(*t* − *τ*) in the synthesis term. Finally, the release from the reserve pool *RP*~*FSH*~ increases blood *FSH* levels, and *FSH* decreases linearly modeled by a clearance term. $$\frac{d}{dt}RP_{LH} = \frac{V_{0,LH} + \frac{V_{1,LH}E_{2}^{8}}{Km_{LH}^{8} + E_{2}^{8}}}{1 + P_{app}/Ki_{LH,P}} - \frac{k_{LH}\lbrack 1 + c_{LH,P}P_{app}\rbrack RP_{LH}}{1 + c_{LH,E}E_{2}}$$ $$\frac{d}{dt}LH = \frac{1}{v}\frac{k_{LH}\lbrack 1 + c_{LH,P}P_{app}\rbrack RP_{LH}}{1 + c_{LH,E}E_{2}} - a_{LH}LH$$ $$\frac{d}{dt}RP_{FSH} = \frac{V_{FSH}}{1 + InhA(t - \tau)/Ki_{FSH,InhA}} - \frac{k_{FSH}\lbrack 1 + c_{FSH,P}P_{app}\rbrack RP_{FSH}}{1 + c_{FSH,E}E_{2}^{2}}$$ $$\frac{d}{dt}FSH = \frac{1}{v}\frac{k_{FSH}\lbrack 1 + c_{FSH,P}P_{app}\rbrack RP_{FSH}}{1 + c_{FSH,E}E_{2}^{2}} - a_{FSH}FSH$$

During a normal cycle estrogen exhibits a 2-stage effect on LH synthesis. Low levels of estrogen inhibit LH release, high levels strongly stimulate production \[[@pcbi.1007848.ref022]\]. This 2-stage behavior is represented by [Eq (1)](#pcbi.1007848.e006){ref-type="disp-formula"}: the synthesis term contains a Hill function dependent on E2, which at a critical level of E2 increases LH synthesis, and in the second term E2 inhibits LH release. The Hill function represents the main biological mechanism of the hypothalamus/pituitary model as it is responsible for the mid-cycle LH surge in response to rising E2 levels. As E2 increases above a threshold level, the Hill function in the first term in [Eq (1)](#pcbi.1007848.e006){ref-type="disp-formula"} becomes large enough to produce the priming affect of E2 on LH synthesis.

In Eqs ([1](#pcbi.1007848.e006){ref-type="disp-formula"})--([4](#pcbi.1007848.e009){ref-type="disp-formula"}) there are important relationships between E2 and P4 in the synthesis and release of gonadotropins. Although E2 is responsible for simulating synthesis through the Hill function, it also inhibits the release of both LH and FSH which is a secondary mechanism of estrogen based contraception. In the positive term in [Eq (1)](#pcbi.1007848.e006){ref-type="disp-formula"}, the denominator contains the secondary contraceptive effect of progestin inhibiting LH synthesis.

### Ovarian model {#sec008}

The ovarian model tracks sensitive follicle mass as it moves through the biological phases of the menstrual cycle: follicular phase and luteal phase (see [Fig 1](#pcbi.1007848.g001){ref-type="fig"}). To simulate the timing of follicle development, the model breaks each of the phases into multiple stages and adds two compartments as a transition from the follicular to luteal phase labeled *Sc*1 and *Sc*2, which represent two stages of the follicle during ovulation. Ovarian hormone production is derived from the mass in each stage in the auxiliary equations. It is assumed that serum concentrations of the ovarian hormones are at a quasi-steady state, i.e., that the hormone concentration is proportional to the masses. This is an assumption formulated in \[[@pcbi.1007848.ref027]\] and used in model construction in the original menstrual cycle model \[[@pcbi.1007848.ref012], [@pcbi.1007848.ref014]\], later modified by Margolskee and Selgrade \[[@pcbi.1007848.ref015]\].

The full system of equations describing the ovarian stages (Eqs ([5](#pcbi.1007848.e010){ref-type="disp-formula"})--([13](#pcbi.1007848.e018){ref-type="disp-formula"})) and associated auxiliary equations (Eqs ([14](#pcbi.1007848.e019){ref-type="disp-formula"})--([17](#pcbi.1007848.e022){ref-type="disp-formula"})) are adopted from \[[@pcbi.1007848.ref014], [@pcbi.1007848.ref015]\]. The follicular phase is broken into 3 stages: recruited follicle (*RcF*), growing follicle (*GrF*), and dominant follicle (*DomF*). The mass tracked cannot be thought of directly as mass of the follicles, but as mass of follicle contributing to hormone production. Estrogen is produced by follicles in the mid to late follicular phase and in the late luteal phase, so the auxiliary equation for estrogen ([Eq (14)](#pcbi.1007848.e019){ref-type="disp-formula"}) consists of terms proportional to the masses in the *GrF*, *DomF*, and *Lut*~4~. Ovulation is broken into two stages and the luteal phase into four stages. Equations calculating ovarian hormones, assumed proportional to masses in different stages, are in Eqs ([14](#pcbi.1007848.e019){ref-type="disp-formula"})--([17](#pcbi.1007848.e022){ref-type="disp-formula"}). In Eqs ([14](#pcbi.1007848.e019){ref-type="disp-formula"}) and ([15](#pcbi.1007848.e020){ref-type="disp-formula"}) exogenous doses of estrogen (*e*~*dose*~) and progestin (*p*~*dose*~) are added, respectively. We assume that the added hormone (progestin or estrogen) acts as the endogenous hormone. [Eq (16)](#pcbi.1007848.e021){ref-type="disp-formula"} defines the variable *P*~*app*~, which groups the effects of progesterone on both the brain and the ovaries, i.e., we assume that P4 affects all tissues in the same way. In the ovaries, during follicle development, P4 limits sensitivity to FSH \[[@pcbi.1007848.ref020], [@pcbi.1007848.ref021]\] as described by the denominator of [Eq (5)](#pcbi.1007848.e010){ref-type="disp-formula"}.

The second term in [Eq (16)](#pcbi.1007848.e021){ref-type="disp-formula"} represents the increase in P4 receptor expression due to E2 \[[@pcbi.1007848.ref023], [@pcbi.1007848.ref028]\] in the form of an increasing Hill function. Hence, the presence of estrogen enhances the effectiveness of P4.

The variable *P*~*app*~ is used everywhere progesterone has an effect, as discussed in detail in the modeling contraception section below. $$\frac{d}{dt}RcF = \left( {b + c_{1}RcF} \right)\frac{FSH}{\left( {1 + P_{app}/Ki_{RcF,P}} \right)^{\xi}} - c_{2}LH^{\alpha}RcF$$ $$\frac{d}{dt}GrF = c_{2}LH^{\alpha}RcF - c_{3}LH\mspace{720mu} GrF$$ $$\frac{d}{dt}DomF = c_{3}LHGrF - c_{4}LH^{\gamma}DomF$$ $${\frac{d}{dt}Sc_{1}}{= c_{4}LH^{\gamma}DomF - d_{1}Sc_{1}}$$ $${\frac{d}{dt}Sc_{2}}{= d_{1}Sc_{1} - d_{2}Sc_{2}}$$ $${\frac{d}{dt}Lut_{1}}{= d_{2}Sc_{2} - k_{1}Lut_{1}}$$ $${\frac{d}{dt}Lut_{2}}{= k_{1}Lut_{1} - k_{2}Lut_{2}}$$ $${\frac{d}{dt}Lut_{3}}{= k_{2}Lut_{2} - k_{3}Lut_{3}}$$ $${\frac{d}{dt}Lut_{4}}{= k_{3}Lut_{3} - k_{4}Lut_{4}}$$ $$E_{2}{= e_{0} + e_{1}GrF + e_{2}DomF + e_{3}Lut_{4} + e_{dose}}$$ $$P_{4}{= p_{0} + p_{1}Lut_{3} + p_{2}Lut_{4} + p_{dose}}$$ $$P_{app} = \frac{P_{4}}{2}(1 + \frac{E_{2}^{\mu}}{Km_{P_{app}}^{\mu} + E_{2}^{\mu}})$$ $${InhA}{= h_{0} + h_{1}DomF + h_{2}Lut_{2} + h_{3}Lut_{3}}$$

Modeling contraception {#sec009}
----------------------

Progestin and estrogen act through different pathways and mechanisms to cause a contraceptive state. Progestin acts by limiting follicular sensitivity to FSH and by inhibiting LH synthesis, whereas estrogen inhibits LH release. Two important autocrine effects in the model capture the basic dynamics of both combined hormonal contraceptives and progestin only treatments. The first is contained in [Eq (5)](#pcbi.1007848.e010){ref-type="disp-formula"} via inhibition of FSH at the ovarian level due to *P*~*app*~. The second, described by [Eq (16)](#pcbi.1007848.e021){ref-type="disp-formula"}, enhances the effect of P4 in the presence of estrogen.

It should be noted that the model tracks blood concentrations of ovarian hormones, exogenous progestin and estrogen levels.

Therefore contraceptive "doses" always refer to concentrations. To analyze model dynamics for each contraceptive treatment, model simulations must have reached stable behavior (cyclic or steady state) ensuring that effects of initial conditions have dissipated. To achieve this, we administered the contraceptive drugs three months prior to analyzing simulation results.

The new model studied here is based on the model in Margolskee and Selgrade \[[@pcbi.1007848.ref015]\], which cannot predict contraceptive behavior. For instance, if a progestin dose of 1.3 ng/mL is administered to the Margolskee and Selgrade model \[[@pcbi.1007848.ref015]\], it results in a slightly higher LH surge than the normal. This occurs because a small additional amount of P4 is more effective at increasing FSH production (see [Eq (4)](#pcbi.1007848.e009){ref-type="disp-formula"}) than inhibiting LH production (see [Eq (1)](#pcbi.1007848.e006){ref-type="disp-formula"}). More FSH causes increased early follicular growth ([Eq (5)](#pcbi.1007848.e010){ref-type="disp-formula"} without the *P*~*app*~ term) resulting in more early follicular E2 and hence a slightly higher LH surge. Including the *P*~*app*~ term without the E2 enhancement of [Eq (16)](#pcbi.1007848.e021){ref-type="disp-formula"} in [Eq (1)](#pcbi.1007848.e006){ref-type="disp-formula"} dampens this growth and decreases the LH surge but it still is at an ovulatory level. Thus in order to model progestin's contraceptive effect both the inhibition of P4 on early follicular development and the enhancement due to E2 are needed to predict contraception.

In the following we describe how the new model components achieve contraception by progestin, estrogen, and the combined treatments.

### Progestin based contraception {#sec010}

The major mechanism of interest is the inhibiting effect progestin has on FSH's ability to produce follicular tissue that is sensitive to LH. A secondary effect present in [Eq (1)](#pcbi.1007848.e006){ref-type="disp-formula"} is P4's inhibition of LH synthesis. It is believed that the hormonal contraceptive effect of progestin is inhibiting growth of active follicular tissue during the early follicular phase by reducing follicular sensitivity to FSH \[[@pcbi.1007848.ref016]\].

This effect is included by introducing *P*~*app*~ in [Eq (5)](#pcbi.1007848.e010){ref-type="disp-formula"}, which inhibits *RcF* growth due to FSH. Under normal conditions, the P4 concentration is very low during this part of the cycle, so the inhibitory effect on follicle growth is negligible. Two growth terms proportional to FSH in [Eq (5)](#pcbi.1007848.e010){ref-type="disp-formula"} are divided by a term including the applied progestin. As a result, FSH has less of a stimulatory effect on follicle growth if the applied progestin is high, such as during treatment with a contraceptive drug or during the luteal phase. These abnormal conditions diminish follicle tissue sensitivity to LH, which inhibits the follicle tissue movement through the normal stages. In addition, the progestin effect is increased by E2 via the Hill function in *P*~*app*~ (see [Eq (16)](#pcbi.1007848.e021){ref-type="disp-formula"}). Thus little appreciable follicular mass can reach the growing follicle stage *GrF*, preventing the mid-cycle rise in E2. Without the rise in E2, the LH surge does not happen and ovulation cannot occur.

### Estrogen based contraception {#sec011}

Estrogen is contraceptive as well. This comes from inhibiting the release of both LH and FSH from the pituitary, modeled by Eqs ([1](#pcbi.1007848.e006){ref-type="disp-formula"}) and ([3](#pcbi.1007848.e008){ref-type="disp-formula"}). The end result is the same as with progestin. Insufficient gonadotropins from the pituitary prevent a LH surge. The addition of estrogen to the treatment allows for a smaller dose of progestin.

### Combined hormonal contraception {#sec012}

In the combined treatment with estrogen and progestin, estrogen serves to bolster progesterone's effect but also inhibits LH release \[[@pcbi.1007848.ref001]\]. The presence of estrogen upregulates progesterone receptor expression, which increases P4's effectiveness. This has been shown in ovine and rat uterine cells \[[@pcbi.1007848.ref001], [@pcbi.1007848.ref028]\]. A possible secondary effect of the the mid-cycle rise in estrogen is to prime P4 receptors for the luteal phase \[[@pcbi.1007848.ref028]\]. To represent this dynamic we have added [Eq (16)](#pcbi.1007848.e021){ref-type="disp-formula"}, which scales circulating P4 in the body with a steep Hill function dependent on estrogen. The resulting *P*~*app*~ is used as the active progesterone in the system. Without estrogen *P*~*app*~ is half of the produced P4. At a certain level of estrogen the receptor expression is assumed higher and *P*~*app*~ approaches P4. In addition, the Hill function in [Eq (16)](#pcbi.1007848.e021){ref-type="disp-formula"} depends on estrogen causing progestin to be effective at lower doses if there is also an estrogen component.

Model summary {#sec013}
-------------

The model described above is formulated as a system of 13 delay differential equations of the form $$\begin{array}{r}
{\frac{dx}{dt} = f\left( x,y,t,t - \tau \right),} \\
\end{array}$$ where $$\begin{array}{r}
{x = \left\{ RP_{LH},LH,RP_{FSH}\left( t - \tau \right),FSH,RcF,GrF,DomF,Sc_{1},Sc_{2},Lut_{1},Lut_{2},Lut_{3},Lut_{4} \right\}} \\
\end{array}$$ with four auxiliary equations for the ovarian hormones $$\begin{array}{r}
{y = \left\{ E_{2},P_{4},P_{app},InhA \right\}} \\
\end{array}$$ and 46 parameters given in [Table 1](#pcbi.1007848.t001){ref-type="table"}. Estimated parameters are marked in bold and the remaining parameters are from \[[@pcbi.1007848.ref015]\]. New parameters are marked by a \*.

The clearance rate for FSH is from \[[@pcbi.1007848.ref029]\]. The clearance rate for LH is from \[[@pcbi.1007848.ref030]\]. Equations are solved with MATLAB using the delay differential equation solver (dde23) and bifurcation analysis is done using DDE-BIFTOOL \[[@pcbi.1007848.ref031]\].

To analyze this model we conducted four simulations studying:

-   The model prediction of baseline hormones without contraception. These results were compared to data repeated over three cycles of length 28 days. Results are compared to data from Figure 1 in Welt et al. \[[@pcbi.1007848.ref025]\].

-   The response with contraception for low and and high dose of progestin, comparing the response to the normally cycling data from Figure 1 in Welt et al. \[[@pcbi.1007848.ref025]\] and the contraceptive state extracted from Figure 1 and Table 3 in \[[@pcbi.1007848.ref016]\].

-   The response with contraception for low and and high dose of estrogen, comparing the response to the normally cycling data from Figure 1 in Welt et al. \[[@pcbi.1007848.ref025]\]. This simulated response is not compared to data.

-   The response to combined treatment with low doses of progestin and estrogen. The low doses used here are the same studied in the isolated treatment studies. Results for this simulation is compared to data from Figure 1 and Table 3 in Mulders and Dieben \[[@pcbi.1007848.ref018]\].

All simulated results are displayed after the solution has reached stable constant or oscillating behavior.

In addition to forward simulations comparing the response to different dosing strategies, we conduct a bifurcation analysis to determine when the model goes from stable oscillations to steady state with the combined estrogen/progestin contraception. Finally, we study the effect of removing contraception to understand how long it takes to return to normal cycling.

Results {#sec014}
=======

This study presents a mathematical model of the menstrual cycle that can predict normal cycling as well as the dynamic response to exogenous progestin and estrogen dosing as described in the model summary section.

[Fig 3](#pcbi.1007848.g003){ref-type="fig"} shows the model's fit to data for normal cycling women digitized from Figure 1 in Welt et al. \[[@pcbi.1007848.ref025]\]. The data is for a single cycle and we have concatenated it for the number of cycles necessary to compare simulations. In this study, we use the term "total contraception" to describe a contraceptive treatment which results in model simulation reaching steady state, i.e., all variables become constant. While biological contraception is achieved before total contraception, quantitatively it is useful to look at where total contraception takes place for comparative analysis. In all plots, data are represented by magenta dot-dashed lines and model simulations by solid blue lines. Unless otherwise stated, asymptotic solutions of a stable cycle or a steady state are displayed. Dosing is applied 3 months before time zero and continues throughout the simulations.

![Normal cycle.\
Results for a normal cycle with no exogenous estrogen or progestin. The model output for 84 days (3 cycles) is denoted by the solid blue line and the connected points are data with error bars digitized from Figure 1 in Welt et al. \[[@pcbi.1007848.ref025]\].](pcbi.1007848.g003){#pcbi.1007848.g003}

Notice that the hormone profiles in [Fig 3](#pcbi.1007848.g003){ref-type="fig"} are not as close to the Welt data \[[@pcbi.1007848.ref025]\] as the profiles in the original model by Clark et al. \[[@pcbi.1007848.ref014]\] are to the data in McLachlan et al. \[[@pcbi.1007848.ref032]\], which Clark et al. \[[@pcbi.1007848.ref014]\] used to identify parameters. This occurs because the Welt data is noisier than the McLachlan data, so parameter identification in Clark et al. \[[@pcbi.1007848.ref014]\] is more accurate. However, the McLachlan data does not contain inhibin B which we will use in the future to improve this study.

Model parameters for this study were largely kept at the values used in the study by Margolskee and Selgrade \[[@pcbi.1007848.ref015]\], except for changes needed for the new model components. New parameters and parameters associated with contraception were estimated and these are marked with bold in [Table 1](#pcbi.1007848.t001){ref-type="table"}. The estimated cycle length is 28.65 days, therefore [Fig 3](#pcbi.1007848.g003){ref-type="fig"} displaying the contraception free result is not completely in phase with the data. We have depicted results aligning the data to the middle of the three cycles. It is possible to adjust the cycle length by scaling the ovarian model parameters *e*~*i*~ and *p*~*i*~, but we chose not to do so to keep the model as close as possible to the original model, and the estimated cycle is still within normal values. Moreover, the objective of this study is to predict the effect of contraception, and the qualitative results discussed below are not dependent on matching the cycle length exactly to the data.

Progestin based contraception {#sec015}
-----------------------------

With the addition of exogenous progestin, the model approaches a contraceptive state in a dose-dependent manner. Data for a contraceptive state due to progestin are taken from Figure 1 and Table 3 in Obruca et al. \[[@pcbi.1007848.ref016]\]. The data display the mean maximum and standard deviation of the hormonal values after a 21 day treatment of a progestin based contraceptive. The mean maximum value is denoted with the red solid horizontal line and the standard deviation is represented by the red dotted horizontal line in Figs [4](#pcbi.1007848.g004){ref-type="fig"} and [5](#pcbi.1007848.g005){ref-type="fig"}. Data (dashed-dotted magenta lines) from Figure 1 in Welt et al. \[[@pcbi.1007848.ref025]\] for a normal cycle are plotted for reference in the figures. Results from both a low and a high dose of progestin are shown (Recall, the model tracks blood concentrations, which we refer to as doses).

![Progestin low dose.\
Model results with a low dose (*p*~*dose*~ = 0.6 ng/mL) are plotted with a solid blue line, while the solid red horizontal red line denotes the mean maximum hormonal values resulting from the 21 day progestin treatment reported in Figure 1 and Table 3 in Obruca et al. \[[@pcbi.1007848.ref016]\] with the standard deviation represented by the horizontal dashed lines. The mid-cycle LH surge has been eliminated. With this dose we have reached biological contraception by preventing the LH surge, but we have not reached total contraception. For comparison, the normal cycling data are presented by a dashed-dotted magenta line.](pcbi.1007848.g004){#pcbi.1007848.g004}

![Progestin high dose.\
Model results with high a dose \**p*~*dose*~ = 1.3 ng/mL are plotted with a solid blue line, while the solid red horizontal line represents the mean maximum hormonal value resulting from the 21 day progestin treatment reported in Figure 1 and Table 3 in Obruca et al. \[[@pcbi.1007848.ref016]\] with the standard deviation represented by the horizontal dashed lines. For P4 we note a significant difference between model predictions and the data. This likely stems from the fact that in the model P4 includes both endogenous and exogenous progestin, while the data only measure the endogenous levels. We have reached a steady state here and thus total contraception. For comparison, the normal cycling data are presented by a dashed-dotted magenta line.](pcbi.1007848.g005){#pcbi.1007848.g005}

Notice that in Figs [4](#pcbi.1007848.g004){ref-type="fig"}--[7](#pcbi.1007848.g007){ref-type="fig"} the FSH profiles in response to contraceptive treatments are higher than biologically observed \[[@pcbi.1007848.ref018]\]. This occurs in our model because FSH synthesis is suppressed only by inhibin A (see [Eq (3)](#pcbi.1007848.e008){ref-type="disp-formula"}). In our model of contraception, ovulation does not occur so the corpus luteum does not develop and InhA is produced at low levels (see [Eq (17)](#pcbi.1007848.e022){ref-type="disp-formula"}). Hence, a considerable amount of FSH is synthesized and the FSH profile is high. Inhibin B is produced during the follicular phase of the cycle and would provide inhibition of FSH in a contraceptive situation. However, including inhibin B would complicate the present model significantly.

![Estrogen low dose.\
Model results (solid blue line) with *e*~*dose*~ = 40 pg/mL. In this simulation, LH has a small mid-cycle rise, but the large LH surge is significantly suppressed and ovulation does not occur indicating a contraceptive state, yet the hormone levels still vary during the cycle. For comparison, the normal cycling data are presented by a dashed-dotted magenta line.](pcbi.1007848.g006){#pcbi.1007848.g006}

![Estrogen high dose.\
Model results (solid blue line) with *e*~*dose*~ = 92 pg/mL. For this high dose total contraception has been achieved. For comparison, the normal cycling data are presented by a dashed-dotted magenta line.](pcbi.1007848.g007){#pcbi.1007848.g007}

The doses giving the hormone levels discussed above from Figure 1 and Table 3 in Obruca et al. \[[@pcbi.1007848.ref016]\] are in mg, whereas in the model they are given in concentrations. Approximate concentration doses were obtained by converting the high dose values reported in Table 3, \[[@pcbi.1007848.ref016]\]. These were subsequently adjusted to obtain a high dose, representing the lowest concentration giving a constant long-term solution. The low does was set to approximately half the high dose. More specifically, for the high dose *p*~*dose*~ = 1.3 ng/mL and for the low dose *p*~*dose*~ = 0.6 ng/mL.

This low dose does not result in total contraception, but the LH surge has been effectively eliminated (see [Fig 4](#pcbi.1007848.g004){ref-type="fig"}) likely causing biological contraception. In [Fig 5](#pcbi.1007848.g005){ref-type="fig"} the high dose case (*p*~*dose*~ = 1.3 ng/mL) is displayed and steady state has been reached, i.e., our defined total contraception.

Estrogen based contraception {#sec016}
----------------------------

While estrogen only contraceptives are not normally used in practice, a high enough dose of estrogen results in contraception. As with progestin, two cases are considered: a low dose that does not cause total contraception and a higher one that does. The low dose case (40 pg/mL) is depicted in [Fig 6](#pcbi.1007848.g006){ref-type="fig"}. Again, the low dose does not achieve total contraception, but the LH surge has been reduced to a level that likely indicates biological contraception. The dose (92 pg/mL) that accomplishes total contraception is shown in [Fig 7](#pcbi.1007848.g007){ref-type="fig"}. In both figures, we have plotted data from \[[@pcbi.1007848.ref025]\] for reference to a normal cycle. Data for estrogen only contraception in humans is unavailable, but hormonal values fall within a reasonable biological range for a contraceptive state.

Combined hormonal contraception {#sec017}
-------------------------------

Applying the two low doses to the model at the same time yields the results shown in [Fig 8](#pcbi.1007848.g008){ref-type="fig"}. Model hormone predictions are compared with values taken from Figure 1 and Table 3 in Mulders and Dieben \[[@pcbi.1007848.ref018]\]. The dotted red horizontal line is the median of the maximum concentration of the hormone between days 8 and 13 of treatment. The solid horizontal line is the predicted hormone concentration output from the model, and for comparison, the normal cycling data are presented by a dashed-dotted magenta line.

![Combined low dose.\
Model results (solid blue line) with *p*~*dose*~ = 0.6ng/mL and *e*~*dose*~ = 40 pg/mL. The dotted red line is the median maximum hormonal value during days 8-14 of combined hormonal treatment reported in Figure 1 and Table 3 in Mulders and Dieben \[[@pcbi.1007848.ref018]\]. These are the two low doses that did not reach total contraception when used individually. The application of both low doses though has achieved total contraception. For comparison, the normal cycling data are presented by a dashed-dotted magenta line.](pcbi.1007848.g008){#pcbi.1007848.g008}

Bifurcation analysis {#sec018}
--------------------

A bifurcation is a change in qualitative behavior of a system and occurs as a parameter of the system crosses a critical value. A Hopf bifurcation occurs when moving over this critical value causes a change from cyclic behavior to steady state behavior or vice versa. If the model is in a cyclic state, a significant enough increase in *p*~*dose*~, *e*~*dose*~, or both will move the model over a Hopf bifurcation from the cyclic region into steady state region. The curve in the (*e*~*dose*~, *p*~*dose*~) space of Hopf bifurcations then illustrates where total contraception is achieved.

The curve in [Fig 9](#pcbi.1007848.g009){ref-type="fig"} displays Hopf bifurcations in the (*e*~*dose*~, *p*~*dose*~) space illustrating the relationship between doses and total contraception. This curve is constructed using the software DDE-BIFTOOL \[[@pcbi.1007848.ref031]\], which identifies bifurcations for delay differential equations. We know that if *p*~*dose*~ = 0 then the system attains a steady state at *e*~*dose*~ = 92 pg/mL, see [Fig 7](#pcbi.1007848.g007){ref-type="fig"}. If *e*~*dose*~ is decreased from 92 pg/mL, DDE-BIFTOOL finds the Hopf bifurcation at *e*~*dose*~ ≈ 90 pg/mL. We fix the *p*~*dose*~ parameter at small increments between 0 and 1.3 pg/mL and search for Hopf bifurcation with respect to the parameter *e*~*dose*~ to generate the curve of Hopf bifurcations in [Fig 9](#pcbi.1007848.g009){ref-type="fig"}. Below the curve are periodic solutions of the model (cyclic behavior) and above the curve are steady state solutions. The normal state of the model is at (0, 0) where there is no dose of either type. The Hopf bifurcations define the doses at which total contraception takes place: the exact point at which the periodic solution becomes a steady state solution. The high dose cases for estrogen and progestin are shown as stars on the *x* and *y* axis respectively. The combination low dose is marked just above the Hopf curve in the steady state solution space in red. The two high dose treatments can be found along either axis where the Hopf curve intersects: for progestin only at *p*~*dose*~ ≈ 1.3 ng/mL and for estrogen only at *e*~*dose*~ ≈ 92 pg/mL.

![Hopf bifurcations.\
Bifurcation diagram representing location of Hopf bifurcations in the (*e*~*dose*~, *p*~*dose*~) space. Solutions below the curve of Hopf bifurcations are periodic and solutions above the curve are steady state. Our total contraception as we have defined it then occurs along this curve of Hopf bifurcations. Any doses falling above the curve are totally contraceptive and any below are not. The low dose combination that we tested (used in [Fig 8](#pcbi.1007848.g008){ref-type="fig"}) is shown with a red star and falls just into the steady state region. The progestin (used in [Fig 5](#pcbi.1007848.g005){ref-type="fig"}) and estrogen (used in [Fig 7](#pcbi.1007848.g007){ref-type="fig"}) only doses can be seen approximately where the Hopf curve intersects the axes.](pcbi.1007848.g009){#pcbi.1007848.g009}

Return to normal cycling {#sec019}
------------------------

All results presented up to this point have been asymptotic solutions that have allowed time for the model to reach a stable cycle or steady state solution. It is imperative, however, in contraceptive design that introduction of a contraceptive quickly cause a non-ovulatory state and removal of the contraceptive results in return to normal cycling. To demonstrate this behavior the model simulates nine cycles assuming cycles are 28 days. The first three cycles are normal, the next three cycles have a combined low dose of estrogen and progestin, and the last three cycles have the dose in the blood exponentially decaying due to the drug's half-life. Both elimination half-lives of the drugs are short compared to the model time scale: progestin has an approximate half-life of a day \[[@pcbi.1007848.ref033], [@pcbi.1007848.ref034]\] and estrogen of two days \[[@pcbi.1007848.ref035]\]. The resulting simulation is shown in [Fig 10](#pcbi.1007848.g010){ref-type="fig"}. The vertical dotted lines represent the beginning and end of dosing. The simulation transitions from a normal cycling state to a contraceptive state and back to normal cycling within one to two cycles of the treatment's removal. The contraceptive portion of the simulation does not have time to reach a steady state, but is completely devoid of an LH surge. The combined dose given is strong enough to cause total contraception if treatment was applied for a longer window.

![Temporary dose.\
Simulation (solid blue line) of a temporary treatment of a low dose combined hormonal contraceptive. Dosing begin at day 84 (green dashed line) and ends at day 168 (red dashed line) at which point the dose decreases exponentially due to the half-life of the drug. A nearly instant contraceptive effect after dosing is observed and, once the drug is removed, return to ovulation occurs within 1-2 cycles.](pcbi.1007848.g010){#pcbi.1007848.g010}

Discussion {#sec020}
==========

In this study, we developed a model for menstrual cycle dynamics that can predict the effects of several contraceptive hormone treatments preventing ovulation. New key features in this model are the ovarian autocrine effects: progesterone inhibiting growth of the recruited follicle and estrogen amplifying the effects of progesterone shown in Eqs ([5](#pcbi.1007848.e010){ref-type="disp-formula"}) and ([16](#pcbi.1007848.e021){ref-type="disp-formula"}), respectively. Data from the biological literature \[[@pcbi.1007848.ref025]\] are used to identify model parameters and the resulting model simulations approximate well the hormonal profiles of normally cycling women ([Fig 3](#pcbi.1007848.g003){ref-type="fig"}).

Then the model is used to test the effects of five different hormonal contraceptive treatments. It is assumed that the doses of exogenous hormones are added directly to the blood and act as the natural analogues in the body. Low and high doses (concentrations) of exogenous progestin reduce the LH surge to non-ovulatory levels (Figs [4](#pcbi.1007848.g004){ref-type="fig"} and [5](#pcbi.1007848.g005){ref-type="fig"}) and reflect clinical data reported in Figure 1 and Table 3 by Obruca et al. \[[@pcbi.1007848.ref016]\] for progestin treatments. In fact, the high dose progestin results in total contraception, which means that hormonal levels are at steady state because the solutions to the differential equations are constants. Also, low and high doses of exogenous estrogen reduce the LH surge to non-ovulatory levels (Figs [6](#pcbi.1007848.g006){ref-type="fig"} and [7](#pcbi.1007848.g007){ref-type="fig"}). The high dose estrogen results in steady state hormone levels. When low dose estrogen and low dose progestin are administered together, this combined hormonal treatment achieves total contraception ([Fig 8](#pcbi.1007848.g008){ref-type="fig"}) and is compared with clinical data from \[[@pcbi.1007848.ref018]\].

In order to determine which dosing pairs result in total contraception, a Hopf bifurcation curve ([Fig 9](#pcbi.1007848.g009){ref-type="fig"}) is drawn in the (*e*~*dose*~, *p*~*dose*~) plane which separates the plane into a region of steady state solutions and a region of non-constant periodic solutions. For dosing pairs near this curve, LH and P4 levels are low so the menstrual cycles are non-ovulatory. As both dosing amounts decrease, the LH surge increases and the contraceptive effect is gradually lost. If a non-ovulatory LH level is assumed, the model may be used to predict which dosing pairs result in LH at or below that level and, hence, are contraceptive. In clinical settings, the contraceptive effect is reached well before the "total contraception" described by the model. Therefore, the modeling results cannot directly be translated to clinical applications, but if combined with a PKPD model, the ideas put forward here have potential to be used in designing new treatment strategies.

Also, model simulations indicate how quickly a combined contraceptive treatment produces a non-ovulatory menstrual cycle and how fast the cycle returns to normal after the treatment ends. For example, [Fig 10](#pcbi.1007848.g010){ref-type="fig"} shows that the treatment pair (*e*~*dose*~, *p*~*dose*~) = (40 pg/mL, 0.6 ng/mL) results in a contraceptive state in the first cycle after dose application and an ovulatory cycle returns within one or two cycles after the treatment ends.

A limitation of the current model is the assumption that the effect of estrogen on progesterone can be combined into one term *P*~*app*~ that does not differentiate the neuroendocrine verses the ovarian systems, and that *P*~*app*~ has a maximum of P4. In reality the effect likely differs between organs, and it may be that for large concentrations of E2 the *P*~*app*~ is larger than P4, but without additional data we chose this unifying approach. Future studies should explore these possibilities in more detail.

Another limitation is that the predicted FSH response to hormonal treatment. [Eq (3)](#pcbi.1007848.e008){ref-type="disp-formula"} indicates that FSH synthesis only depends on inhibin A. When a contraceptive state is reached, luteinization does not occur and so inhibin A is diminished. Because inhibin A inhibits FSH synthesis, the model predicts that in a contraceptive state FSH is produced at a high level. However, this is not observed biologically \[[@pcbi.1007848.ref018]\]. To improve the model, [Eq (3)](#pcbi.1007848.e008){ref-type="disp-formula"} needs to be modified so that FSH synthesis depends on more reproductive hormones especially inhibin B.

Finally, for each synthetic exogenous hormone, the addition of a model accounting for its pharmacokinetics and its specific activity in relation to the corresponding natural hormone would allow for more detailed representation of different treatments. While the addition of a model of this type can give insight into specific treatments, it does not change the main conclusions that contraception can be achieved at a lower dose for the combined treatments.

In summary, this study presents a mathematical model which accurately predicts daily hormone levels (LH, FSH, E2, P4, InhA) for normally cyling women. By adding two ovarian autocrine effects of E2 and P4 and only four new parameters to previous models \[[@pcbi.1007848.ref012]--[@pcbi.1007848.ref015]\] we have studied, this new model illustrates that progestin and synthetic estrogen treatments result in contraception. When coupled with a PKPD model for oral contraceptive drugs, the resulting model may help discover minimal effective doses of these drugs and may lead to patient-specific dosing strategies.

For this study, we would like to acknowledge Drs. Tjeerd Korver and Michelle Fox for their scientific input and advice while the model was being developed and refined. We would also like to thank the two referees whose suggestions have significantly improved this manuscript. This work was developed in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, where Andrew Wright held an internship.
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The question of variability in contraceptive dosing is an interesting one, especially where hybrid treatments are concerned. On the one hand, the approach used by the authors\--modifying an existing framework to account for additional roles for relevant hormones\--is appropriate to study such a problem. However, it seems the description of the approach and explanation of why certain modeling choices were made are lacking in this manuscript. Descriptions of the work, beginning with the \"Modeling contraception\" section should be written in a more detailed and clear way, especially as far as modeling assumptions and their justification, and methods in exploring the edose-pdose parameter space are concerned. The organizational structure of the paper works as is, but would benefit from a great deal more detail about the simulation methods\--in addition to the assumption previously mentioned\--particularly with respect to distinguishing between previously used and new parameters, parameter estimation (if applicable), and the major differences between the approach in the paper compared to that of the experiment.

In addition, the manuscript would benefit from additional editing for typos, grammar, and general flow of the writing. There are also several terms that are used with inconsistent punctuation (hyphenated, etc.) and improper use of open quotation marks, which I assume are due LaTeX\'s idiosyncrasies.

Specific Major Comments

\- Page 12-13

\- Eqn (5): It is not clear why the choice is made to separate b and c1 as parameters, particularly when they are both multiplied by the FSH variable and scaled by a function of Papp. Why not just define a single parameter equivalent to b+c1, since these would not be independently identifiable anyway?

\- Eqn (16): There appear to be two primary effects of exogenous progestin on the system: (1) the neuroendocrine effects involved in regulating LH synthesis and (2) the ovarian autocrine effect of reducing FSH sensitivity of follicles. The authors do not provide sufficient justification for making the modeling choices reflected in Equation (16). In particular, if E2 is meant to upregulate P4 receptors, effectively increasing P4 function, there is no differentiation between neuroendocrine and ovarian mechanisms. That is, the choice of E2-mediated feedback in Eqn 16 seems to reflect how E2 behaves in the hypothalamic-pituitary axis rather than in ovarian tissues (looking at the forms used in the original model). If the feedback modeled is universal in all tissues, then this should be stated explicitly in the manuscript.

In addition, if E2 primes P4 receptors for the luteal stage, why would this effect be reflected in follicle growth in the same way that P4 works to inhibit gonadotropins when elevated throughout the luteal stage? Is there a good explanation as to why E2-dependent Papp might affect different tissues from regularly circulating P4? I suggest that the authors explore this possibility for the sake of completeness.

It is also not clear why the priming effect of E2 can only maximally double the effective P4 concentration. Since explicit receptor expression and binding kinetics are not modeled here, it is unclear how the model chosen is mechanistically appropriate. The most general model for Eqn (16) might have the form Papp = (P4/(1+Z))\*(1+ Z\*Hill(E_2)), where Z is not necessarily 1 (as is currently the case). Have the authors already explored this possibility? If so, this should be mentioned in the manuscript, with a justification of the final form for Equation (16). If not, it may be useful to explore the dynamics of the model for various scalings.

Specific Minor Comments

1 - Page 3, Table 1: Are there references for the parameters used, especially those that are part of the modification? Or if most parameters used come from existing models, please also mention this.

2 - Page 5, line 99: The wording for \"not well understood mechanisms\" is awkward. Please consider fixing this.

3 - Page 7, lines 134-135: Are the functions of LH mentioned here also normal functions of endogenous progesterone?

4 - Page 9, Fig. 2: The hormones listed in the caption and appearing in the blue boxes include P2. Is this supposed to be P4 instead?

5 - Page 10, Eqns (3) and (4): There appears to be a typo in the denominator of the FSH release terms (1 + c_FSH,E \* E_2), where E_2 should be squared. The units for c_FSH,E appearing in Table 1 are consistent with the Schlosser/Selgrade model, but this term is not.

6 - Page 11, lines 217 and 218: The description of estrogen and progestin doses being added lacks subject-verb agreement. Please check the specifics.

7 - Page 13, line 243: The FSH-dependent growth term mentioned is not actually \"scaled by a factor proportional to applied progestin\" as it appears in Eq (5). The terminology should be fixed in this sentence to match what is reflected in the equation in question.

8 - Page 13, lines 263-264: Statement beginning with \"Insufficient gonadotropins\...\" is incomplete (fragment).

9 - Page 14, lines 275-276: Were any parameters estimated in the model fitting process? If so these should be explicitly indicated, either in the table of parameters or in the Results section. If not, the authors should give a description of how new parameters for the model addition were chosen.

10 - Page 15, Fig. 3 & description: How many cycles of data were used in the model fitting? What is the cycle length from the new model without contraceptives compared to the data? Is there any insight to the discrepancy between the model and the data? How does the baseline model (no estrogen/progestin) compare to the original model without the new modifications? An illustration of this might be useful for the average reader.

11 - Page 21, Fig. 9: \"Low Dose Combination\" is spelled incorrectly. Please add units to the axes in the graph as well. Also, it is not at all described how the bifurcation diagram was generated. Was this through ad hoc methods or using some other software? Please clarify. Further, because the manuscript places emphasis on the distinction between total contraception and \"partial\" contraception with periodic solutions, it would be useful to overlay regions within the periodic solutions for which some level of contraception is obtained (clinical criterion), even if this is not valid mathematically. This also seems relevant in the context of limiting contraception doses to clinically effective values, rather than mathematically effective values. More emphasis on the physiological and clinical relevance would be helpful in the discussion of model results.

12 - Page 22, lines 343-344: Please provide references for the half-lives of progestin and estrogen. Also, are the half-lives of exogenously administered hormones different from endogenous ones?

13 - Page 24, line 388: The authors comment on the shortcoming of the model, which may require that FSH synthesis be modeled using additional reproductive hormones. I assume the authors are referring to Inhibin B, among others. If this is the case, the known hormones should be stated explicitly.

14 - General: In the Results section, it is left unclear whether the doses used in the simulations are used to match the data in reference \[15\] or whether they reflect the minimum doses required to elicit total (or partial) contraception. The bifurcation diagram certainly matches these values, but it is unclear whether this is a by-product of the model itself or whether the parameters were tuned to match experimental data. Please clarify.

Reviewer \#2: Review of PCOMPBIOL-D-19-01189, Mechanistic model of hormonal contraception

General comments

The paper describes an augmentation of a previously published model of hormonal regulation of the menstrual cycle, through addition of two autocrine terms, and demonstrates model predictions given low and high dosing of estrogen alone, progesterone alone (nominally as progestin), and a combination of the two. The model has potential utility in designing hormone dosing regimens to achieve birth control, characterized by an acyclic state with low LH throughout, and also to elucidate what mechanism of the female reproductive cycle are key to explaining observed responses to birth control regimens. Unfortunately, the paper as is lacks sufficient detail to achieve either of these, but I believe that a small amount of additional work could help it to meet these objectives. I also suggest ways in which the results could be significantly improved, but those could be discussed as potential future research.

For context, I have experience in the mathematical modeling of endocrine/hormonal systems, but not in contraception science. One way in which the model could be useful is that researchers seeking to refine birth control methods (combinations of estrogen and progesterone capable of achieving birth control) might use it to identify regimens that will achieve this purpose. But to be convinced that it can be used for this purpose, I would want to know that it can accurately predict the result of existing regimens. The authors demonstrate an ability to simulate partial and complete birth control, but how do the doses used in the modeling that achieve these effects (low and high estrogen, for example) compare to corresponding clinical doses? There is a brief reference to progestin levels in \[15\], made towards the end of the introduction, but the specific levels used in those experiments and the current simulations (and rationale for them) should be described in the methods section on modeling contraception. Further, the P4 and FSH predictions in Figure 5, for example, are well outside the observed ranges. Off hand these decrease my confidence in the model's ability to predict hormonal response to contraceptive dosing. At a minimum, I suggest that the authors discuss how the simulated estrogen and progesterone (progestin) compare to doses used in the study which they simulate. Better would be to explore what model parameters or features would need to be adjusted such that all predicted hormone levels are within the experimental range from \[15\], Obruca et al. (2006). A rough sensitivity analysis could provide the later.

A very interesting qualitative result stated in the paper, but not really shown, is that two autocrine terms had to be added to the ovarian model in order for the birth control regimens to be successfully described. But the authors don't show predictions of the original model, without these terms: how badly does the original model fail to predict contraceptive dosing response? What happens if only one of the autocrine terms is added? How did the authors determine that both were necessary? In short, show me that \*both\* additional terms are needed for the model to perform successfully, by showing how it fails without them, or with only one of them.

Also, please provide references to biological sources which describe these autocrine mechanisms... reference for the effect of progestins on follicle sensitivity to FSH \[15, 19\] are given in the "Contraceptive mechanisms" section, but these should be repeated in the "Ovarian model" section, where the mode equations are being described. I did not see references for the autocrine effect of estrogen. The supporting literature/data should be cited along with the description of the corresponding equations.

Also, how where the forms and the parameters of the autocrine terms selected? They are fairly standard Hill-like forms, but how were the values of the coefficients obtained? It's fine if this was a simple attempt to fit data, but then that should be stated. Where they arrived at by trial-and-error, or formal optimization? Implicit in the estrogen autocrine term (equation 16) is that the effect varies between a maximum of 1 (100%) and 0.5 (50%). How was this range identified? Are there supporting data? Were other ranges from minimal to maximal induction considered?

Specific comments

While it is nice to augment figures with color, keep in mind that 10% of people (readers) are color blind. Different line types (short dash, long dash, dot-dash, etc.) and/or colors that are distinguishable when printed in grey-scale should be used.

P. 5, first line: \*usually\* a single follicle will advance to ovulation. Sometimes it's more than one! (This is said later but should be said here.)

The term "applied progesterone" (for equation 16, first introduced at the bottom of p. 11) lacks biological meaning. The specific autocrine effect being described is induction of the progesterone receptor. A separate term, really equation (16) but for P4, should be defined as the scaled progesterone receptor (PR) expression. Since the maximum of this term is 1, it PR expression / maximal PR expression. The degree of PR activation is then defined as the product of P4 and PR expression. This product could also be called progesterone signal.

I checked the cited references for the original model \[12, 13\] and another by those authors (Clark et al., 2003) and saw that that version of the model better replicated FSH peak, which this version appears to badly under-predict (Figure 3), and the height of the secondary E2 surge. I suspect that when the autocrine terms were added, the original model parameters were not re-tuned to match these features of the normal cycle. When the model structure was changed, the model parameters should have been revised. Is the low FSH peak (relative to the original model) due to the autocrine terms? Also, how is it that the autocrine terms do not extinguish the normal cycle entirely, without exogenous hormones?

And it would be much better if the experimental data in Fig 3 were shown with confidence bounds (error bars), since that would allow a reader to judge whether areas where the fit is poor are at least within the range of variability.

Fig 6: the legend says that the LH surge has been eliminated, but there is still a small peak occur \~ every 33 days. I would say "significantly suppressed" instead.

Fig 9: again, I'd like to know how the P4 and E2 doses used at the three dose levels compare to those actually used.
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Large-scale datasets should be made available via a public repository as described in the *PLOS Computational Biology* [data availability policy](http://journals.plos.org/ploscompbiol/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.
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Dear Prof. Olufsen,

We are pleased to inform you that your manuscript \'Mechanistic model of hormonal contraception\' has been provisionally accepted for publication in PLOS Computational Biology.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.
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The two reviewers felt that your revisions improved the manuscript substantially. As you will see, Reviewer 2 made suggestions of a few additional minor changes that you can consider before uploading final documents.

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The author has addressed all previous comments satisfactorily. No additional comments.

Reviewer \#2: The paper is much improved and could be accepted as written, however I have a few suggestions to be considered.

First, the authors state that to include the PK of the exogenous hormones used for birth control, individual (\"patient-specific) data would be needed. I disagree. The rest of the model is built to describe an average or typical patient, and the parameters of the ovarian and HP models are not patient-specific, so there\'s no reason that population-average PK parameters couldn\'t be used for estrogen and progestin to make that part of the model more realistic.

While the functional form of estrogen\'s effect on P4 sensitivity is realistic, represents qualitatively what might result from a model of progesterone receptor activity, it is quite empirical, especially assuming the same response in the follicles as in the hypothalamus/pituitary. Also, I would assume that the basal level in the absence of E2 is \"1\" and that it increases from there, but the model as is is tuned fairly well to the normal cycle, so there would only be a nominal impact of such a change, as other parameters would need to be changed to offset this change in the P_app term.

Fig 2 legend, 3rd sentence, \"The black horizontal arrows represent hormone movement\....\" This is not true for the ovarian model. There the black arrows represent movement of cells or tissue between stages, which have differing hormone production capacity.

P. 11, line 207, \"The Hill function is the main biological mechanism\...\" I would restate this. A function is just a mathematical construct, it can\'t be a biological mechanism. But it can represent a mechanism. Can you briefly say what biological mechanism is being represented and why the term is so important to the model?
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